GU Cancers 2023 | Combining radiotherapy and IO for patients with oligometastatic RCC

Shankar Siva, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, talks on a recent study combining radiotherapy and pembrolizumab for patients with oligometastatic kidney cancer. The trial reported that the combination therapy had similar toxicity to the monotherapies and had the potential to be more beneficial for patients with high-volume disease than either radiotherapy or immunotherapy alone. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.